Induction of Antigen-Specific Tolerance in a Multiple Sclerosis Model without Broad Immunosuppression

Area of Science:

• Neuroimmunology
• Biomaterials Science
• Drug Delivery Systems

Background:

• Multiple sclerosis (MS) is a debilitating autoimmune disease affecting the central nervous system.
• Current MS treatments use broad immunosuppression, increasing infection risk.
• There is a critical need for therapies that induce antigen-specific tolerance.

Purpose of the Study:

• To develop and evaluate a novel tolerogenic particle-based therapy for MS.
• To investigate the efficacy of antigen-specific immunotherapy in preclinical MS models.
• To assess the safety and immune competence preservation of the novel therapy.

Main Methods:

• Engineered spray-dried particles from acetalated dextran, loaded with myelin oligodendrocyte glycoprotein (MOG) peptide and rapamycin.
• Tested particles in a MOG-induced experimental autoimmune encephalomyelitis (EAE) mouse model of MS.
• Administered treatment at early symptom onset and during peak disease; assessed antigen specificity using influenza hemagglutinin (HA) immunization.

Main Results:

• Particles significantly reduced clinical scores in early and late therapeutic EAE models.
• Treatment reversed hind limb paralysis and restored limb function in mice with peak disease.
• Therapy did not suppress antibody responses to a non-cognate antigen (HA), indicating preserved immune competence.

Conclusions:

• Engineered particles demonstrate potent therapeutic effects in reversing established MS-like autoimmunity.
• The antigen-specific nature of the therapy preserves overall immune function, a key advantage over current treatments.
• This particle-based approach holds significant promise for developing safer and more effective MS therapies.